Cabozantinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), G-BA (Germany) and HIRA (South Korea) recommended or restricted cabozantinib, while CIPM (Spain), CONITEC (Brazil) and DMC (Denmark), among others, did not recommend it.
On the same population the two systems disagree outright: NICE (England) recorded restricted in TA542, while PBAC (Australia) recorded not recommended for “Renal cell carcinoma (RCC)”.
SMC (Scotland) has been harder on cabozantinib than on its own caseload: it refused 3 of 7 decisive submissions here (43%), against a base rate of 16% across everything it has assessed.
Assessment has run over 11.6 years, from 29 Jan 2015 at AWMSG (Wales) to 10 Aug 2026 at AIFA (Italy).
SMC (Scotland) changed its position: not recommended on 9 Mar 2015, restricted by 10 Aug 2026, after a resubmission.
No assessment is on file from HAS (France), which is among the eight highest-volume agencies here.
The file is active: 19 of 56 records date from 2023 or later.
The programme is broad: 19 distinct indication wordings are recorded for cabozantinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
9 of these 56 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess cabozantinib, on 29 Jan 2015; PHARMAC (New Zealand) did not open a file until 16 Jun 2026 — an unusually long tail of 11.4 years between the earliest and latest system to look at it.
The record arrives in waves: 11 separate years each carry two or more decisions, spread across 12 years in total.
9 of the 15 agencies here assessed cabozantinib more than once, PBAC (Australia) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
cabozantinib has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for cabozantinib reads 16 not recommended, 15 recommended, 10 restricted and 6 deferred to NICE, with 9 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AIFA (Italy) | 10 Aug 2026 | CABOMETYX è indicato per il trattamento di pazienti adulti affetti da tumori neuroendocrini ben differenziati extra-panc… | fully innovative status not granted · reimbursed class H | source |
| PBAC (Australia) | 2026 | Clear cell variant renal cell carcinoma | In March 2026, the PBAC extended its March 2024 recommendation for this drug for a further… | source |
| DMC (Denmark) | 24 Jun 2026 | Cabometyx er indiceret til behandling af voksne patienter med inoperable eller metastatiske, veldifferentierede ekstra-p… | Ikke anbefalet | source |
| PHARMAC (New Zealand) | 16 Jun 2026 | advanced clear cell renal cancer, second line therapy | PTAC advice: Decline | source |
| AOTMIT (Poland) | 2 Jun 2026 | Cabometyx reimbursement recommendation | recommended conditionally | source |
51 further decisions for cabozantinib, across 14 agencies, are not shown here. They include the most recent record on file, 10 Aug 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 43 further source documents.
Related molecules
- avelumab — divergent outcome (not recommended vs recommended) on a shared indication
- regorafenib — divergent outcome (not recommended vs recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
Coverage: 56 decisions for cabozantinib from 15 agencies, 2015 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.